Cancers · 2022 · 38 citations · 29 references
MedicineOncologyPathologyMetastasisMolecular OncologyTumor ProgressionCancer BiomarkersLung CancerLung MetastasisTumor AntigensTumor MarkersTumor-associated AntigensBiomarkers For Metastatic DiseaseCancer Metastasis BiomarkersDistant Metastasis DetectionDistant Metastasis StagingLymphatic Metastasis BiomarkersMetastatic BiomarkersPredictive Tumor MarkersSerum Tumor Markers
Objective: This study aimed to explore the roles of serum tumor markers for metastasis and stage of non-small cell lung cancer (NSCLC). Methods: This study recruited 3272 NSCLC patients admitted to the Tianjin Union Medical Center and the Tianjin Medical University Cancer Institute and Hospital. The predictive abilities of some serum tumor markers (carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), cytokeratin-19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP), total prostate-specific antigen (TPSA) and carbohydrate antigen 199 (CA199)) for NSCLC metastasis (intrapulmonary, lymphatic and distant metastasis) and clinical stage were analyzed. Results: Tumor markers exhibited different numerical and proportional distributions in NSCLC patients. Elevated CEA, CYFRA 21-1 and CA199 levels were indicative of tumor metastasis and stage. Increased CEA and CA199 provided an accurate prediction of intrapulmonary and distant metastasis with the area under the receiver operator characteristic curve (AUC) of 0.69 both (p < 0.001); Increased CEA, CYFRA 21-1 and CA199 provided an accurate prediction of lymphatic metastasis with the AUC of 0.62 (p < 0.001). Conclusion: Combined detection of serum tumor markers can indicate tumor metastasis and stage in NSCLC patients.
29
Maria Giovanna Dal Bello, Rosangela Filiberti, Angela Alama et al. · Journal of Translational Medicine · 2019 · 203 citations · Full text
Medicine, Oncology, Pharmacology +17